DOCSLIB.ORG

Voriconazole

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Voriconazole Drug and Biologic Coverage Policy Effective Date ............................................ 6/1/2020 Next Review Date… ..................................... 6/1/2021 Coverage Policy Number .................................. 4004 Voriconazole Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 2 General Background ............................................ 2 Coding/Billing Information .................................... 4 References .......................................................... 4 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Coverage Policy This coverage policy addresses the use of oral voriconazole. The use of intravenous voriconazole is not addressed in this coverage policy. Voriconazole (Vfend®) is considered medically necessary when ANY of the following criteria are met: • Aspergillosis and EITHER of the following, o Prophylaxis post transplantation o Treatment of invasive infection • Empiric therapy in febrile neutropenic individuals • Prophylaxis for an individual at high-risk for neutropenia (for example, allogeneic hematopoietic stem cell transplant [HSCT] recipients, individuals undergoing either intensive remission-induction or salvage-induction chemotherapy for acute leukemia) • Invasive or severe candida infections (for example, abdomen, bladder wall, candidemia, esophageal, kidney, oropharyngeal, skin) AND, o Documented failure or contraindication per FDA label, intolerance to, or not a candidate for fluconazole • Meningoencephalitis or pulmonary disease caused by cryptococcosis AND, o Documented failure or contraindication per FDA label, intolerance to, or not a candidate for fluconazole • Fungal infection caused by Scedosporium apiospermum and Fusarium spp. Page 1 of 5 Coverage Policy Number: 4004 • CNS blastomycosis • Coccidioidomycosis AND, o Documented failure or contraindication per FDA label, intolerance to, or not a candidate for fluconazole or itraconazole • Histoplasmosis AND, o Documented failure or contraindication per FDA label, intolerance to, or not a candidate for itraconazole • Prophylaxis or treatment of a systemic fungal infection in HIV-infected individuals Voriconazole is considered medically necessary for continued use when the individual continues to meet the initial criteria. Initial and reauthorization is up to 12 months unless otherwise stated. Voriconazole is considered experimental, investigational, or unproven for any other use. When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy. Note: Receipt of sample product does not satisfy any criteria requirements for coverage. FDA Approved Indications FDA Approved Indication Vfend is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: • Invasive aspergillosis • Candidemia in non-neutropenics and other deep tissue Candida infections • Esophageal candidiasis • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy Recommended Dosing FDA Recommended Dosing Vfend tablets or oral suspension should be taken at least one hour before or after a meal. See full prescribing information for instructions on oral administration of Vfend in adults and pediatric individuals 2 years of age and older. Drug Availability Tablets Supplied as 50 mg and 200 mg tablets in bottles of 30. Generic formulations of voriconazole tablets are also available. Powder for Oral Suspension Supplied as 45 g of powder for oral suspension in a bottle providing a usable volume of 70 mL. General Background Pharmacology Voriconazole is a broad-spectrum triazole antifungal which inhibits fungal cytochrome P450 mediated 14 alpha- lanosterol demethylation and disrupts the synthesis of ergosterol, resulting in abnormal fungal cell membrane. Page 2 of 5 Coverage Policy Number: 4004 Professional Societies/Organizations Infectious Diseases Society of America (IDSA) Aspergillosis Early initiation of antifungal therapy in individuals with strongly suspected invasive aspergillosis is warranted while a diagnostic evaluation is conducted. Because of better survival and improved responses of initial therapy with voriconazole, primary therapy with deoxycholate amphotericin B (D-AMB) is not recommended. For primary treatment of invasive pulmonary aspergillosis, IV or oral voriconazole is recommended for most individuals. Oral therapy can be maximized by using a dose of 4 mg/kg rounded up to convenient tablet sizes. For seriously ill individuals, the parenteral formulation is recommended. (IDSA, 2016) Candidiasis For esophageal candidiasis, fluconazole is the treatment of choice for esophageal candidiasis. For fluconazole- refractory disease, itraconazole, posaconazole or voriconazole may be administered. Ketoconazole and itraconazole capsules are less effective than fluconazole because of variable absorption. Voriconazole is as effective as fluconazole and has also useful in treating mucosal candidiasis refractory to fluconazole. For oropharyngeal candidiasis, fluconazole is the treatment of choice. For fluconazole refractory disease, itraconazole or posaconazole may be administered. Voriconazole may be considered as third-line therapy when treatment with other agents has failed. For candidemia in the non-neutropenic setting, intravenous voriconazole is effective for candidemia, but offers little advantage over intravenous fluconazole as initial therapy. Voriconazole is recommended as step-down oral therapy for selected cases of candidemia due to Candida krusei. In neutropenic individuals, intravenous voriconazole can be used in situations in which additional mold coverage is desired. Voriconazole can also be used as step-down therapy during neutropenia in clinically stable individuals who have had documented bloodstream clearance and isolates that are susceptible to voriconazole. (IDSA, 2016) Coccidioidomycosis Fluconazole and itraconazole are considered first line therapies, while voriconazole is reserved for treatment failures. More severe disease (for example, severe osseous infections) requires intravenous amphotericin B with subsequent transition to long term azole therapy. (IDSA, 2016) Histoplasmosis Voriconazole has been used in a limited number of individuals with various forms of histoplasmosis and is considered a second-line alternative to itraconazole. (IDSA, 2007) Neutropenia Antifungal therapy is appropriate in neutropenic individuals who have persistent unexplained fever, despite receipt of 4–7 days of broad-spectrum antibacterial therapy. The choice of antifungal agent is based on likely fungal pathogens (e.g., if individual was on antifungal prophylaxis), toxicities, and cost. Amphotericin B has been the standard empirical antifungal agent used for decades with recent trials evaluating potential alternatives. A randomized trial in individuals with neutropenia and persistent fever did not demonstrate that voriconazole was non-inferior to liposomal amphotericin B as empiric antifungal therapy. However the authors noted that voriconazole was superior to amphotericin B in reducing documented breakthrough fungal infections, infusion- related toxicity, and nephrotoxicity and was similar in individual elements of the composite score. (Walsh, 2002) National Comprehensive Cancer Network (NCCN) The NCCN
Load more

Recommended publications
  • 012402 Voriconazole Compared with Liposomal Amphotericin B
    The New England Journal of Medicine Copyright © 2002 by the Massachusetts Medical Society VOLUME 346 J ANUARY 24, 2002 NUMBER 4 VORICONAZOLE COMPARED WITH LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN PATIENTS WITH NEUTROPENIA AND PERSISTENT FEVER THOMAS J. WALSH, M.D., PETER PAPPAS, M.D., DREW J. WINSTON, M.D., HILLARD M. LAZARUS, M.D., FINN PETERSEN, M.D., JOHN RAFFALLI, M.D., SAUL YANOVICH, M.D., PATRICK STIFF, M.D., RICHARD GREENBERG, M.D., GERALD DONOWITZ, M.D., AND JEANETTE LEE, PH.D., FOR THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES MYCOSES STUDY GROUP* ABSTRACT NVASIVE fungal infections are important caus- Background Patients with neutropenia and per- es of morbidity and mortality among patients sistent fever are often treated empirically with am- receiving cancer chemotherapy or undergoing photericin B or liposomal amphotericin B to prevent bone marrow or stem-cell transplantation.1-3 invasive fungal infections. Antifungal triazoles offer IOver the past two decades, empirical antifungal ther- a potentially safer and effective alternative. apy with conventional amphotericin B or liposomal Methods In a randomized, international, multi- amphotericin B has become the standard of care in center trial, we compared voriconazole, a new sec- reducing invasive fungal infections in patients with ond-generation triazole, with liposomal amphoteri- neutropenia and persistent fever.4-9 Amphotericin B, cin B for empirical antifungal therapy. however, is associated with significant dose-limiting Results A total of
    [Show full text]
  • Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre Yeastone and CLSI Microdilution Methods
    Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods Xue Ting Tan ( [email protected] ) National Institute of Health, Malaysia Stephanie Jane Ginsapu National Institute of Health, Malaysia Fairuz binti Amran National Institute of Health, Malaysia Salina binti Mohamed Sukur National Institute of Health, Malaysia Surianti binti Shukor National Institute of Health, Malaysia Research Article Keywords: Voriconazole, Sensititre, CLSI, Mould Posted Date: February 12th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-199013/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Background: Voriconazole is a trizaole antifungal to treat fungal infection. In this study, the susceptibility pattern of voriconazole against lamentous fungi was studied using Sensititre® YeastOne and Clinical & Laboratory Standards Institute (CLSI) M38 broth microdilution method. Methods: The suspected cultures of Aspergillus niger, A. avus, A. fumigatus, A. versicolor, A. sydowii, A. calidoutus, A. creber, A. ochraceopetaliformis, A. tamarii, Fusarium solani, F. longipes, F. falciferus, F. keratoplasticum, Rhizopus oryzae, R. delemar, R. arrhizus, Mucor sp., Poitrasia circinans, Syncephalastrum racemosum and Sporothrix schenckii were received from hospitals. Their identication had been conrmed in our lab and susceptibility tests were performed using Sensititre® YeastOne and CLSI M38 broth microdilution method. The signicant differences between two methods were calculated using Wilcoxon Sign Rank test. Results: Mean of the minimum inhibitory concentrations (MIC) for Aspergillus spp. and Fusarium were within 0.25 μg/mL-2.00 μg/mL by two methods except A. calidoutus, F. solani and F. keratoplasticum.
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • Itraconazole (Sporonox ) & Voriconazole (Vfend )
    Itraconazole (Sporonox) & Voriconazole (Vfend) These are broad spectrum, anti-fungal agents that can be taken orally. They are very expensive approx $800- $1100/month). Although both these prescription medications are FDA approved for the treatment of mold or fungal infections, they do not have a specific indication for the treatment of fungal rhinosinusitis. Molds appear to be present in everyone's nasal and sinus passageways but in some individuals, the molds appear to cause disease. The explanation for this is unknown (See What is Rhinosinusitis?). As such, Insurers resist covering them for treatment of rhinosinusitis associated with the presence of molds. Itraconazole • Your liver enzymes will be monitored by periodically by blood tests. • Take your Itraconazole dose at the same time everyday. • Take your medication after a full meal. • Antacids can reduce absorption of this medication and if need be they should be taken at least 1 hour before or 2 hours after taking Itraconazole. • If you are taking stomach medication, make sure you drink cola beverage with the Itraconazole to help it become absorbed. • Report any signs or symptoms of unusual fatigue, anorexia, nausea and/or vomiting, jaundice (yellowing skin), dark urine, or pale stools. • Other potential side effects include elevated liver enzymes, gastrointestinal disorders, rash, hypertension, orthostatic hypertension, headache, malaise, myalgia, vasculitis, edema, and vertigo. • Contact your practitioner BEFORE beginning any new medications while taking Itraconazole. • Women should use effective measures to PREVENT pregnancy during and up to 2 months after finishing itraconazole. • Itraconazole should not be taken with a class of cholesterol-lowering drugs known as statins, unless your physicians has specifically told you to do so.
    [Show full text]
  • Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date
    PEER REVIEWED Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-use Date ABSTRACT Pradeep Gautam, MS Chemistry A novel compounding vehicle (RECURA) has previously been proven to Bob Light, BS, RPh penetrate the nail bed when compounded with the antifungal agent miconazole or fluconazole, providing for an effective treatment for onychomycosis. In this Troy Purvis, PhD study, miconazole and fluconazole were compounded separately in RECURA compounding cream, and they were tested at different time points (0, 7, 14, 28, 45, 60, 90, and 180 days), determining the beyond-use date of those INTRODUCTION formulations. The beyond-use date testing of both formulations (10% Onychomycosis is a fungal infection of miconazole in RECURA and 10% fluconazole in RECURA) proved them to be the nail bed in the fingers, or more com- physically, chemically, and microbiologically stable under International monly the toes, which affects an estimated Conference of Harmonisation controlled room temperature (25°C ± 2°C/60% 1 10% of the world’s population. Trichophy- RH ±5%) for at least 180 days from the date of compounding. Stability- ton is the typical fungal genus that causes indicating analytical method validation was completed for the simultaneous these infections in Western countries, while determination of miconazole and fluconazole in RECURA base using high- those living tropical regions experience Candida, Aspergillus, or Scytaldium infec- performance liquid chromatography coupled with photodiode array detector tion,2 but the symptoms of these infections prior to the study. are similar across the board. Minor infec- tion causes a yellow or black thickening of the nail bed, while further progression can 48% cure rate),1 yet concern about long- These medications must be in direct contact result in the nail chipping away and leaving term dosing and severe side-effects due to with the fungus in order to kill it.5 The FDA- an open sore, leading to secondary infec- oral administration exists.
    [Show full text]
  • The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 August 28. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1815–1822. doi:10.1093/cid/ciy813. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016 Jennifer R. Cope1, Janet Landa1,2, Hannah Nethercut1,3, Sarah A. Collier1, Carol Glaser4, Melanie Moser5, Raghuveer Puttagunta1, Jonathan S. Yoder1, Ibne K. Ali1, Sharon L. Roy6 1Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2James A. Ferguson Emerging Infectious Diseases Fellowship Program, Baltimore, MD, USA 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA 4Kaiser Permanente, San Francisco, CA, USA 5Office of Financial Resources, Centers for Disease Control and Prevention Atlanta, GA, USA 6Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract Background—Balamuthia mandrillaris is a free-living ameba that causes rare, nearly always fatal disease in humans and animals worldwide. B. mandrillaris has been isolated from soil, dust, and water. Initial entry of Balamuthia into the body is likely via the skin or lungs. To date, only individual case reports and small case series have been published. Methods—The Centers for Disease Control and Prevention (CDC) maintains a free-living ameba (FLA) registry and laboratory. To be entered into the registry, a Balamuthia case must be laboratory-confirmed.
    [Show full text]
  • DIFLUCAN® (Fluconazole Tablets) (Fluconazole for Oral Suspension)
    ® DIFLUCAN (Fluconazole Tablets) (Fluconazole for Oral Suspension) DESCRIPTION DIFLUCAN® (fluconazole), the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, as a powder for oral suspension. Fluconazole is designated chemically as 2,4-difluoro-α,α1-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical formula of C13H12F2N6O and molecular weight of 306.3. The structural formula is: OH N N N N CH2 C CH2 N F N F Fluconazole is a white crystalline solid which is slightly soluble in water and saline. DIFLUCAN Tablets contain 50 mg, 100 mg, 150 mg, or 200 mg of fluconazole and the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, povidone, croscarmellose sodium, FD&C Red No. 40 aluminum lake dye, and magnesium stearate. DIFLUCAN for Oral Suspension contains 350 mg or 1400 mg of fluconazole and the following inactive ingredients: sucrose, sodium citrate dihydrate, citric acid anhydrous, sodium benzoate, titanium dioxide, colloidal silicon dioxide, xanthan gum, and natural orange flavor. After reconstitution with 24 mL of distilled water or Purified Water (USP), each mL of reconstituted suspension contains 10 mg or 40 mg of fluconazole. CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral routes. In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration. Bioequivalence was Reference ID: 4387685 established between the 100 mg tablet and both suspension strengths when administered as a single 200 mg dose. Peak plasma concentrations (Cmax) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 to 50 hours) after oral administration.
    [Show full text]
  • Treatment of Visceral Leishmaniasis with Intravenous Pentamidine And
    International Journal of Infectious Diseases 14 (2010) e522–e525 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Case Report Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure — a case report and brief review of the literature Jan Rybniker a, Valentin Goede a, Jessica Mertens b, Monika Ortmann c, Wolfgang Kulas d, Matthias Kochanek a, Thomas Benzing e, Jose´ R. Arribas f, Gerd Fa¨tkenheuer a,* a 1st Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany b Department of Gastroenterology, University of Cologne, Cologne, Germany c Institute of Pathology, University of Cologne, Cologne, Germany d Nephrologisches Zentrum Mettmann, Mettmann, Germany e Department of Medicine and Centre for Molecular Medicine, University of Cologne, Cologne, Germany f Enfermedades Infecciosas, Hospital Universitario La Paz, Madrid, Spain ARTICLE INFO SUMMARY Article history: We report the case of an HIV-positive patient with visceral leishmaniasis and several relapses after Received 3 March 2009 treatment with the two first-line anti-leishmanial drugs, liposomal amphotericin B and miltefosine. End- Accepted 4 June 2009 stage renal failure occurred in 2007 when the patient was on long-term treatment with miltefosine. A Corresponding Editor: William Cameron, relapse of leishmaniasis in 2008 was successfully treated with a novel combination regimen of Ottawa, Canada intravenous pentamidine and oral fluconazole. Secondary prophylaxis with fluconazole monotherapy did not prevent parasitological relapse of leishmaniasis. Keywords: ß 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Visceral leishmaniasis HIV Fluconazole Pentamidine Miltefosine Renal failure 1.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Cutaneous Sporotrichosis of Face: Polymorphism and Reactivation After Intralesional Triamcinolone
    Case Report CCutaneousutaneous sporotrichosissporotrichosis ofof face:face: PolymorphismPolymorphism andand reactivationreactivation afterafter iintralesionalntralesional triamcinolonetriamcinolone NNandand LLalal Sharma,Sharma, KKaranaran InderInder SSinghingh MMehta,ehta, VVikramikram K.K. MMahajan,ahajan, AAnilnil KK.. KKanga*,anga*, VVikasikas CChanderhander SSharma,harma, GitaGita RR.. TTegtaegta Departments of Dermatology, Venereology and Leprosy and *Microbiology, Indira Gandhi Medical College, Shimla, India. Address for correspondence: Dr. N. L. Sharma, Department of Dermatology, Venereology and Leprosy, Indira Gandhi Medical College, Shimla - 171001 (H. P.), India. E-mail: [email protected] ABSTRACT Cutaneous sporotrichosis, a subcutaneous mycotic infection is caused by the saprophytic, dimorphic fungus Sporothrix schenckii. It commonly presents as lymphocutaneous or fixed cutaneous lesions involving the upper extremities with facial lesions being seen more often in children. The lesions are polymorphic. The therapeutic response to saturated solution of potassium iodide is almost diagnostic.We describe a culture-proven case of cutaneous sporotrichosis of the face mimicking lupus vulgaris initially and basal cell carcinoma later, who did not tolerate potassium iodide and failed to respond to treatment with fluconazole. The patient had reactivation of infection following an infiltration of the scar with triamcinolone acetonide injection. Various other aspects of these unusual phenomena are also discussed. .com). Key Words: Cicatricial
    [Show full text]
  • VORICONAZOLE Persists, Consult Your Doctor
    may come back. If the infection worsens or should avoid driving, using machinery or VORICONAZOLE persists, consult your doctor. doing something that may be dangerous if your vision is impaired. Notify your doctor if Other NAMES: Vfend What should you do if you FORGET a your vision changes or if bright lights are dose? bothersome. WHY is this drug prescribed? If you miss a dose voriconazole, take it as What other PRECAUTIONS should you Voriconazole is an antifungal drug. It is used soon as possible. However, if it is time for follow while using this drug? to treat a variety of fungal infections (candida, your next dose, do not double the dose, just aspergillosis) in the mouth (like thrush), carry on with your regular schedule. Before starting voriconazole, please inform esophagus, lungs, blood and in other areas. your doctor if you have ever developed an What ADVERSE EFFECTS can this drug allergy to voriconazole or to similar drugs HOW should this drug be taken? cause? What should you do about them? [ketoconazole (Nizoral ), fluconazole (Diflucan ), itraconazole (Sporanox ). Also Voriconazole is available as 50 mg and 200 Voriconazole may cause some stomach notify your doctor if you have kidney, liver or mg tablets. During the first days of therapy, it upset, nausea, vomiting and loss of vision problems. can also be given by intravenous (I.V.: in the appetite . Some other potential adverse veins) injections. The intravenous injections effects are abdominal pain, diarrhea, and Certain drugs can increase or decrease the will be given over a 1 to 2 hour period, likely headache .
    [Show full text]
  • Miltefosine Treatment Reduces Visceral Hypersensitivity in a Rat Model For
    www.nature.com/scientificreports OPEN Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome Received: 28 February 2019 Accepted: 2 August 2019 via multiple mechanisms Published: xx xx xxxx Sara Botschuijver1, Sophie A. van Diest1, Isabelle A. M. van Thiel 1, Rafael S. Saia1,2, Anne S. Strik1,3, Zhumei Yu1,4,9, Daniele Maria-Ferreira 1,5, Olaf Welting1, Daniel Keszthelyi6, Gary Jennings7, Sigrid E. M. Heinsbroek1,3, Ronald P. Oude Elferink 1,3, Frank H. J. Schuren 8, Wouter J. de Jonge1,3 & René M. van den Wijngaard1,3 Irritable bowel syndrome (IBS) is a heterogenic, functional gastrointestinal disorder of the gut-brain axis characterized by altered bowel habit and abdominal pain. Preclinical and clinical results suggested that, in part of these patients, pain may result from fungal induced release of mast cell derived histamine, subsequent activation of sensory aferent expressed histamine-1 receptors and related sensitization of the nociceptive transient reporter potential channel V1 (TRPV1)-ion channel. TRPV1 gating properties are regulated in lipid rafts. Miltefosine, an approved drug for the treatment of visceral Leishmaniasis, has fungicidal efects and is a known lipid raft modulator. We anticipated that miltefosine may act on diferent mechanistic levels of fungal-induced abdominal pain and may be repurposed to IBS. In the IBS-like rat model of maternal separation we assessed the visceromotor response to colonic distension as indirect readout for abdominal pain. Miltefosine reversed post-stress hypersensitivity to distension (i.e. visceral hypersensitivity) and this was associated with diferences in the fungal microbiome (i.e. mycobiome).
    [Show full text]